Search

everythinglearnresearchcommunity

for

Search:↓

User tried Minoxidil and Finasteride for hair loss with no success and considers giving up. Others suggest continuing treatment, trying hair transplant, or embracing baldness.

User reports 2 months progress using daily oral fin 1mg, twice daily topical min 5%, and intermittent dermapen. Others share their experiences, suggesting patience and additional treatments like alternating shampoos, using conditioner, tretinoin, and vitamins.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.

Hair loss and potential treatments, primarily focusing on Finasteride and Minoxidil. Other solutions discussed include PRP, dermarolling, LLP, and scalp tension relief.

A user's experience with using finasteride and minoxidil to treat hair loss; they experienced minimal regrowth with finasteride alone, but significant regrowth with the combination of finasteride and minoxidil.

User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.

A user experienced significant hair shedding and thinning after using oral castor oil for hair loss. Other users suggested seeing a dermatologist and noted that castor oil is typically used for constipation.

Vat-R-U-Talkin-About: I'm not sure that wearing a hat would have an effect on either Minoxidil or Finasteride. It may be worth experimenting with not wearing one for a few weeks to see if it makes any difference. This conversation is about a user's progress pictures four months into taking minoxidil, finasteride, and nizoral twice weekly to treat hair loss; others shared their experiences and offered advice on how to improve the treatment.

User hears aunt's comment on hair loss during Easter gathering. Others discuss handling rude comments and share experiences with hair loss treatments like Minoxidil and Finasteride.

Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.

Rice water was used as a hair treatment and showed noticeable results in a week, more than finasteride used for seven months. The user plans to continue using rice water and might stop finasteride, while still using ketoconazole for dandruff.

Creatine use with finasteride increased DHT levels, possibly affecting hair loss. The user plans to reduce creatine to stabilize DHT and hair shedding.

User noticed balding 3 years ago and started using finasteride 11 months ago. Recently tried Toppik hair fibers, which improved appearance and boosted confidence.

The user experienced severe side effects from overdosing on saw palmetto and is considering starting a low dose of finasteride for hair loss, despite concerns about similar side effects. Most responses advise against using finasteride due to potential risks, suggesting consulting a doctor and addressing underlying health issues first.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

A user is experiencing significant hair loss and stress, seeking advice on treatments. They are using Pura d'or shampoo and conditioner, biotin, and considering other options but are hesitant about treatments like Minoxidil due to the need for continuous use.

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The conversation is about the effectiveness of RU58841 after stopping its use. The user is concerned about losing results if there's a 4-5 day gap before the next bottle arrives.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.